A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Phase 2 Terminated
50 enrolled 18 charts
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Phase 2 Terminated
5 enrolled
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
Phase 2 Terminated
3 enrolled 12 charts
ARIANES
Phase 2 Terminated
130 enrolled
BIS-Program
Phase 2 Terminated
33 enrolled
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Phase 2 Terminated
12 enrolled
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Phase 2 Terminated
11 enrolled 10 charts
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Phase 2 Terminated
46 enrolled
LOST-B
Phase 2 Terminated
1 enrolled
ABE-LIVER
Phase 2 Terminated
3 enrolled
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Phase 2 Terminated
4 enrolled 9 charts
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Phase 2 Terminated
4 enrolled 10 charts
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Phase 2 Terminated
16 enrolled 12 charts
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Phase 2 Terminated
2 enrolled 1 chart
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Phase 2 Terminated
29 enrolled
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase 2 Terminated
6 enrolled 17 charts
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Phase 2 Terminated
3 enrolled 13 charts
PARCT
Phase 2 Terminated
26 enrolled
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Phase 2 Terminated
7 enrolled 11 charts
TARA
Phase 2 Terminated
1 enrolled 11 charts
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Phase 2 Terminated
24 enrolled
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase 2 Terminated
6 enrolled 18 charts
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
Phase 2 Terminated
1 enrolled 9 charts
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Phase 2 Terminated
169 enrolled 31 charts
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Phase 2 Terminated
30 enrolled 28 charts
ARGO
Phase 2 Terminated
53 enrolled
GELATO
Phase 2 Terminated
23 enrolled
PREDIXIIHER2
Phase 2 Terminated
6 enrolled
CONTESSA TRIO
Phase 2 Terminated
294 enrolled
COM-IT-1
Phase 2 Terminated
21 enrolled
NEO-VC
Phase 2 Terminated
47 enrolled
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
IMDZ-C232
Phase 2 Terminated
89 enrolled 24 charts
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Terminated
3 enrolled 3 charts
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Phase 2 Terminated
5 enrolled 6 charts